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CTCF binding sites are frequently mutated in cancer,
but how these mutations accumulate and whether
they broadly perturb CTCF binding are not well un-
derstood. Here, we report that skin cancers exhibit
a highly specific asymmetric mutation pattern within
CTCF motifs attributable to ultraviolet irradiation and
differential nucleotide excision repair (NER). CTCF
binding site mutations form independently of replica-
tion timing and are enriched at sites of CTCF/cohesin
complex binding, suggesting a role for cohesin in
stabilizing CTCF-DNA binding and impairing NER.
Performing CTCF ChIP-seq in a melanoma cell line,
we show CTCF binding site mutations to be func-
tional by demonstrating allele-specific reduction of
CTCF binding to mutant alleles. While topologically
associating domains with mutated CTCF anchors in
melanoma contain differentially expressed cancer-
associated genes, CTCF motif mutations appear
generally under neutral selection. However, the fre-
quency and potential functional impact of such mu-
tations in melanoma highlights the need to consider
their impact on cellular phenotype in individual ge-
nomes.INTRODUCTION
CCCTC-binding factor (CTCF) is an architectural protein
involved in establishing the three-dimensional organization of
the genome and defining genomic segments by gene expression
(Holwerda and de Laat, 2013). CTCF is a tumor suppressor that
is commonly deleted or mutated in cancer (Filippova et al., 1998;
Kemp et al., 2014; Rakha et al., 2006). Recently, CTCF/cohesin
binding sites have been found to be highly mutated in cancer
(Ji et al., 2016; Kaiser et al., 2016; Katainen et al., 2015; Sabari-
nathan et al., 2016; Umer et al., 2016). Themajority of research toCell Repor
This is an open access article under the CC BY-Ndate has been on CTCF binding site mutations in gastrointestinal
cancers, with associations established between motif mutations
and late replication, presence of cohesin, and signature 17 (Kai-
ser et al., 2016; Katainen et al., 2015; Umer et al., 2016).
Mutations in melanoma and other UV-light-induced skin can-
cers are driven by unique mutational processes associated
with UV light, and many mutations form at transcription factor
binding sites in these cancers because protein-binding impairs
access by nucleotide excision repair (NER) enzymes (Perera
et al., 2016; Sabarinathan et al., 2016). Despite CTCF binding
sites being highly mutated in melanoma (Sabarinathan et al.,
2016), the mutation pattern at the nucleotide level, together
with additional factors contributing to mutation accumulation
at CTCF binding sites have yet to be examined. Importantly,
the functional consequences of these highly prevalent mutations
in skin cancer remain unknown.
In this study, we examined three types of skin cancer: mela-
noma (n = 36), skin squamous cell carcinoma (SCC; NER-profi-
cient XPCwild-type: n = 8; NER-deficient XPC/: n = 5), and skin
basal cell carcinoma (BCC; n = 3), to comprehensively evaluate
CTCF binding site mutations across UV-light-induced cancers.
We examined the mutation profile within the CTCF binding motif,
identifying factors underlying mutation accumulation, which
associate with NER impairment.We also assessed the functional
impact of suchmutations onCTCF binding in cells through allele-
specific chromatin immunoprecipitation sequencing (ChIP-seq)
and, using computational analyses, show that CTCF binding
sitemutations are generally under neutral selection inmelanoma.RESULTS AND DISCUSSION
Mutation Rates at CTCF Motifs in UV-Light-Induced
Cancers
We defined a 13-bp CTCF motif for our analyses as follows:
CCA(CjG)(CjT)AG(AjG)(GjT)GGC(AjG) (shown in Figure 1C).
This strict motif allowed us to minimize false-positive binding
sites which may introduce noise, and to exclude the three low in-
formation-content nucleotides at the 50 and 30 ends of the
consensus CTCF motif from the JASPAR database (Mathelierts 17, 2865–2872, December 13, 2016 ª 2016 The Author(s). 2865
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Prevalence of Mutations at CTCF
Motifs in UV-Light-Induced Cancers
(A) Mutation density permelanoma sample (n = 36)
for region ±1 kb of CTCF motif center.
(B) Mutation rate at CTCF and control motifs in
melanoma and skin squamous, basal, and nucle-
otide excision repair (NER)-deficient XPC/
squamous cell carcinomas (SCC). Boxplot shows
median, quartiles, maximum, and minimum. Black
dots indicate individual cancer samples. Signifi-
cance is by paired t test for each sample.
(C) Mutation density per sample in melanoma and
XPC/ SCC at CTCF motifs and mutations
simulated using the trinucleotide signature of
melanoma or XPC/ SCC. Locations of pyrimi-
dine pairs present in all motifs are indicated.
(D and E) Normalized repair reads for (D) cyclo-
butane pyrimidine dimer (CPD) and (E) (6-4)py-
rimidine-pyrimidone photoproduct ((6-4)PP) XR-
seq across pyrimidine pairs.
Significance is by paired t test between pyrimidine
pairs, with only significant associations shown.
****p<0.0001, ***p<0.001, **p<0.01,and *p<0.05.
See also Figure S1.et al., 2015). To select for bound motifs, we chose motifs within
CTCF ChIP-seq peaks from normal human epidermal keratino-
cytes (NHEK) from ENCODE (ENCODE Project Consortium,
2012). Constructing mutation profiles centered upon these mo-
tifs (n = 5,470; Table S1), we observed an over 20-fold increase
in mutation rate at CTCF motifs in melanoma (Figure 1A), with
mutations similarly increased in other UV-light-induced cancers
including NER-proficient SCC (Figure S1A) and BCC (Fig-
ure S1B). In contrast, NER-deficient XPC/ SCCs showed no
enrichment for mutations at CTCF motifs (Figure S1C), confirm-
ing previous findings that differential NER efficiency leads to
CTCF mutation hotspots (Sabarinathan et al., 2016). (As XPC/
SCCs showed no clear reduction of mutations at CTCF motifs
(Figure S1C), this suggests that CTCF binding is unlikely to signif-
icantly inhibit DNA lesion formation in response to UV light.)
Across all melanoma, NER-proficient SCCs and BCCs, we
found 91% (43/47) of samples to have at least one mutated
CTCF motif (72.1% mean ±4.9% SD when mutations randomly
shuffled). Of all CTCF motifs examined (n = 5,470), we found
8.6% of motifs (n = 468) mutated at least once across the 47
samples, with 52 of those motifs mutated twice (11.1%), and
seven mutated three times (1.5%). Examination of recurrence
at an individual nucleotide level revealed that, of all CTCF motif2866 Cell Reports 17, 2865–2872, December 13, 2016mutations (n = 534), 13 nucleotides were
mutated in two samples, and one nucleo-
tide was mutated in three samples.
These rates of motif mutation recurrence
were substantially higher than what
would be expected by chance alone
(125.7 motifs mutated at least once
±11.1 SD, 1.4 motifs mutated twice
±1.2 SD and 0.008 motifs mutated three
times ±0.10 SD). This suggests that other
factors such as trinucleotide context oraccess by NER machinery underlie the increased CTCF binding
site mutation rate observed.
Differential NER Underlies Asymmetric Mutation
Accumulation within CTCF Motifs in UV-Light-Induced
Cancers
A specific conserved adenine central to the CTCF motif (that is,
position 6; Figure 1C) becomes highly mutated in many cancer
types (Kaiser et al., 2016; Katainen et al., 2015; Umer et al.,
2016). These mutations are associated with a genome-wide mu-
tation signature within the cancer sample consisting of high
numbers of T > C/G mutations (Kaiser et al., 2016; Katainen
et al., 2015). However, such a mutation signature does not
feature prevalently in the genomes of UV-light-induced cancers
(Alexandrov et al., 2013). Instead, we found a highly conserved
guanine pair (positions 10 and 11) to harbor almost 70% (373/
534) of CTCF motif mutations across melanoma (Figure 1C),
SCC (Figure S1D), and BCC (Figure S1E).
Mutations simulated to account for trinucleotide mutation
preferences showed the mutation pattern at CTCF motifs not
to be due to sequence context alone (Figures 1C, S1D, and
S1E). To account for any sequence-dependent mutation rate
variation beyond trinucleotide context, we defined a control
motif (see Figure S1F) within NHEK CTCF ChIP-seq peaks. We
observed only a small increase in mutation rate at the 30 guanine
pair in replication timing-matched control motif (Table S1; Fig-
ures S2D–S2J), likely attributable to significantly lower CTCF
binding at control motifs than actual CTCF motifs (p < 0.0001,
unpaired t test; Figure S1G). Further, the mutation rate was
significantly lower in the control motif than the CTCFmotif inmel-
anoma (p < 0.0001; paired t test) and SCC (p < 0.01; paired t test)
but not NER-deficient XPC/ SCCs (p = 0.8403; Figure 1B),
suggesting that CTCF binding rather than sequence context un-
derlies the highly localized mutation pattern at CTCF motifs.
UV-light-induced cancers accumulate many mutations at CC/
CT/TC dinucleotides (Cleaver and Crowley, 2002), and the CTCF
motif consists of three conserved pyrimidine pairs (see Fig-
ure 1C). Given that XPC/ SCC mutation density is broadly
similar at each pyrimidine pair (Figure 1C), differential cyclobu-
tane pyrimidine dimer (CPD) and (6-4)pyrimidine-pyrimidone
photoproduct (6-4PP) formation is unlikely to account for the
increased mutation load at the 30 guanine pair. In contrast, using
strand-specific CPD and (6-4)PP NER maps (excision repair
sequencing [XR-seq]) (Adar et al., 2016), we found that over
the 48 hr CPD (Figure 1D) and 4 hr (6-4)PP (Figure 1E) time
courses, repair was consistently and significantly lower at the
30 guanine pair than either the 50 cytosine pair (CPD: p < 0.05
and (6-4)PP: p < 0.01, by paired t test) or the central AG (CPD
and (6-4)PP: p < 0.001, by paired t test). While XR-seq data do
not resolve the specific DNA lesion targeted by NER, neverthe-
less, these findings indicate that while NER is generally inhibited
across entire regions of CTCF binding (Sabarinathan et al.,
2016), differential rates of repair at specific pyrimidines within
the CTCF motif may account for the asymmetric mutation accu-
mulation observed at CTCF motifs in skin cancer.
Impairment of NER Is Dependent upon Cohesin at CTCF
Binding Sites
In gastrointestinal cancers and leukemia, most CTCF motif mu-
tations occur at sites of CTCF/cohesin binding (Ji et al., 2016;
Katainen et al., 2015; Umer et al., 2016). However, the relation-
ship between CTCF motif mutations and the cohesin-complex
has not been established in UV-light-induced cancers. By
defining a list of cohesin- and non-cohesin-bound CTCF motifs
using ChIP-seq for RAD21 (a component of the cohesin com-
plex) across eight cell types (Table S2), we found that, consistent
with other cancer types, in melanoma, mutation density is only
increased within cohesin-bound CTCF motifs (Figure 2A).
We next investigated the relationship between NER and the
presence of the CTCF/cohesin complex. Given that the strength
of binding of a transcription factor can impact the degree of NER
impairment at a given locus (Perera et al., 2016; Sabarinathan
et al., 2016), we investigated the influence of cohesin on the rela-
tionship betweenmutations and CTCF binding. Mutation density
was significantly correlated with CTCF binding strength only at
CTCF/cohesin binding sites (p < 0.01 for motifs with RAD21,
p = 0.8056 for motifs without RAD21, Spearman’s correlation;
Figure 2B), though it is worth noting the low numbers of muta-
tions in non-cohesin-boundmotifs whichmay reduce the robust-
ness of the latter correlation. Next, using XR-seq data (Hu et al.,
2015), we constructed profiles of CPD repair surrounding CTCFmotifs. We observed levels of NER to be high at sites immedi-
ately adjacent to CTCF binding, consistent with nucleosome
depletion in these regions, making DNA more accessible to
NER enzymes (Sabarinathan et al., 2016). Compared with these
immediate flanks, we foundNER to be significantly impaired only
at CTCF motifs with cohesin binding (Figure 2C). NER was also
more evidently abrogated at cohesin-bound CTCF motifs with
high rather than low CTCF read coverage (Figure 2D). Our find-
ings suggest that multifactorial impairment of NER, in response
to both CTCF binding strength and the presence of a CTCF/co-
hesin protein complex, underlies mutation accumulation at
CTCF motifs in UV-light-induced cancers.
CTCF Binding Site Mutations Form Independent of
Replication Timing in Skin Cancers
In gastrointestinal cancers, CTCF binding site mutations have
been associated with late replication (Kaiser et al., 2016; Katai-
nen et al., 2015). However, in skin cancers, suchmutations accu-
mulate when CPDs and 6-4PPs are not repaired by NER prior to
DNA replication (Perera et al., 2016; Sabarinathan et al., 2016),
and so we hypothesized that replication timing may not greatly
impact upon mutation accumulation at CTCF motifs. Consistent
with our hypothesis, we found mutation accumulation to signifi-
cantly correlate with replication timing only in motifs with low
CTCF read coverage, but not in motifs with high coverage
(p < 0.05 and p = 0.9239, respectively, Spearman’s correlation;
Figure 2E). Since accumulation of CTCFmotif mutations is corre-
latedwith CTCF binding strength (Figure 2B), mutationswith high
CTCF binding would be more likely than those with low CTCF
binding to be driven by NER impairment from CTCF binding
than by the influences of late replication.
Impact of CTCF Motif Mutations on CTCF Binding in
COLO829
Having identified the specific mutation pattern and amechanism
underlying its formation in UV-light-induced skin cancers, we
sought to determine whether CTCF motif mutations affect
CTCF binding. We performed CTCF ChIP-seq in the melanoma
cell line COLO829. From replicate independent experiments,
we identified 44,050 common CTCF peaks (Figure S2A) and,
within these, 48,603 CTCF motifs (motifs accorded to the
19-bp consensus motif from the JASPAR database [Mathelier
et al., 2015] [shown in Figure 3C]). We found most motifs to be
positioned near the centers of CTCF peaks (Figure S2B), with
some peaks containing multiple motifs.
Using mutations from COLO829 whole-genome sequencing
(WGS) data (Craig et al., 2016), we identified 124 COLO829 mu-
tations in CTCF peaks, of which 16 were within the CTCF motif
(Figure 3A; Table S3). Mutations in CTCF peaks were generally
distributed across the genomewithout a distinct pattern, consis-
tent with the apparent random distribution of mutations in CTCF
peaks in the WGS The Cancer Genome Atlas (TCGA) melanoma
samples (Figure S2C). Of the 15 heterozygous COLO829 muta-
tions in CTCF motifs, eight were at the 30 guanine pair (Figures
3A and 3C; Table S3). Two sites harbored dinucleotidemutations
within the same motif (Table S2).
To identify whether the heterozygous COLO829 CTCF motif
mutations (Table S2) caused allele-specific loss of CTCFCell Reports 17, 2865–2872, December 13, 2016 2867
Figure 2. Mechanism Underlying CTCF Motif Mutation Accumulation in Melanoma
(A) Mutation density per sample for region ±1 kb of CTCF motif center in melanoma, for NHEK CTCF motifs with (left) and without (right) RAD21 binding.
(B) Correlation of mutation density and CTCF ChIP-seq read coverage over NHEK CTCF motifs with (left) and without (right) RAD21 binding.
(C and D) Nucleotide excision repair cyclobutane pyrimidine dimer (CPD) repair profiles using XR-seq (Hu et al., 2015) data for region ±1 kb of NHEK CTCFmotifs
for (C) motifs with matched CTCF reads with and without RAD21 binding and (D) motifs with RAD21 binding, separated into bottom (Q1) and top (Q4) quartiles of
NHEK CTCF read coverage across the motif.
(E)Correlationofmutation rateand replication timing forbottom(Q1; left) and top (Q4; right) quartilesofNHEKCTCF readcoverage, forCTCFmotifswithRAD21binding.
Data points show binned data; significance is by Spearman’s correlation on un-binned data.binding, we examined the normalized variant allele frequency
(normVAF) of mutant alleles from our ChIP-seq data (see Fig-
ure 3B and Experimental Procedures). We found all mutations
at the guanine pair to correspond to an allele-specific decrease
in CTCF binding (<50%normVAF), with six out of eight mutations
with <10% normVAF, indicating a dramatic reduction of CTCF
binding tomutant alleles (Figure 3C). We observed no allele-spe-
cific loss of CTCF binding in mutations beyond the most highly
conserved 13-bp center of themotif (normVAF>50%; Figure 3C).
Considering all mutations in CTCF peaks in COLO829,mutations
within the conserved center 13 bp of the motif had significantly
lower normVAFs than mutations only within CTCF ChIP-seq
peaks (median of 7% versus 48%; p < 0.0001, unpaired t test;
Figure 3D).
To further support our finding that CTCF motif mutations
reduce CTCF binding, we performed in vitro DNA-affinity exper-
iments using a wild-type and mutant CTCF motif (Figure S2D;
see Experimental Procedures). Incubating DNA baits with nu-
clear protein extract from COLO829, we observed loss of
CTCF binding to mutant motifs via western blot (Figure S2E).
Taken together, our experimental analyses demonstrate single
point mutations at highly conserved sites within CTCF motifs,2868 Cell Reports 17, 2865–2872, December 13, 2016especially at the 30 guanine pair, to be sufficient to reduce, or
in some cases entirely abrogate, CTCF binding.
CTCFMotif Mutations as Potential Cancer Driver Events
Having established that CTCF motif mutations can alter CTCF
binding, we next sought to determine whether such mutations
may be potential melanoma drivers. Using topologically associ-
ating domain (TAD) anchor motifs from NHEK cells (Rao et al.,
2014), we identified DNA loops with mutated anchor motifs (n
= 343), and found cancer-associated genes within these loops
(see Experimental Procedures). Of the 16 cancer-associated
genes we identified, using matched TCGA melanoma RNA
sequencing data, we found seven with significantly different
expression inmutant samples (significance by p < 0.05; unpaired
t test or one-sample t test, with Bonferroni method to correct for
multiple testing; Figure S3A). Though it is worth noting the small
melanoma sample size in our analyses (n = 36), making accurate
determinations of significance difficult.
To investigate whether our findings would be expected by
chance alone, we performed a bootstrapping analysis on signif-
icantly differentially expressed anchor-gene-loop groupings
(see Experimental Procedures). The actual fraction of unique
Figure 3. CTCF Motif Mutations and CTCF
Binding in COLO829
(A) Circos plot (Krzywinski et al., 2009) of CTCF
peak and motif mutations in COLO829. Outer
track (heatmap) denotes density of bases of CTCF
peaks per 10 Mb (low, yellow; high, blue). Inner
track (dots) shows CTCF peak mutations (gray),
motif mutations on the 30 guanine pair (red) and
other motif mutations (orange).
(B) Flow chart of allele-specific ChIP-seq analysis
calculating normalized variant allele frequency
(normVAF) for COLO829 mutations in CTCF
peaks.
(C) Mutation count, type and normVAF from
COLO829 ChIP-seq for heterozygous COLO829
mutations in CTCF consensus motifs (shown, per
JASPAR database [Mathelier et al., 2015]).
(D) normVAF of CTCF motif mutations from
COLO829 ChIP-seq, for all mutations within the
center 13 bp of CTCF motifs and peak-only
mutations. Boxplot shows median, quartiles,
maximum, and minimum. Significance by un-
paired t test. ****p < 0.0001.
See also Figure S2.anchor-gene-loop groupings in melanoma with significantly
different gene expression, for both cancer-associated and
non-cancer-associated genes, fell well within the distribution
from randomly shuffled mutations (Figures S3B and S3C).
Further, when we compared the proportion of cancer-associ-
ated genes contained in TADswith either wild-type or mutant an-
chor motifs, we found no enrichment for cancer-associated
genes in mutant loops in melanoma (p = 0.8950, Fisher’s exact
test), nor was the fraction of cancer-associated genes (2.84%;
16/564 genes) significantly different from the mean of the distri-
bution of randomly shuffledmutations (2.90%mean ±0.59%SD;
Figure 4A). We also found no significant difference in melanoma
between the distance from mutated anchors of cancer-associ-
ated and non-cancer-associated genes (p = 0.4132, unpaired t
test, Figure S3D).
Mutations at higher variant allele frequencies (VAFs) are pre-
sent in greater proportions of cancer cells (Sidow and Spies,
2015) and may be more likely than those at lower VAFs to confer
a growth advantage. Hence, we examined the VAFs of mela-
noma mutations in CTCF motifs and peaks, and the VAFs in
our samples of the known melanoma driver mutation BRAF
V600E. We found no significant difference between the VAFs
of CTCF motif and peak mutations (Figure 4B), nor between
CTCF anchor and non-anchor motif mutations (Figure S3E).
However, these mutations generally had significantly lower
VAFs than BRAF V600E mutations (p < 0.0001 or p < 0.001, un-
paired t test; Figures 4B and S3E). It is yet possible that some
CTCF motif mutations (perhaps those at higher VAFs) may act
as cancer drivers in individual samples, but our results suggestCell Reportsthat, in general, somatic mutations in
CTCF motifs are under more neutral se-
lection, and so the majority of such muta-
tions are less likely to be cancer drivers.
While there is evidence that CTCFmotifmutations in gastrointestinal cancers may be enriched near can-
cer-associated genes (Umer et al., 2016), our findings indicate
that this is not generally the case in melanoma. Perhaps UV-
light-induced cancers differ in this way from gastrointestinal
cancers due to the differentmechanismwhich underlies their for-
mation. Specifically, the mechanism of differential NER oper-
ating in UV-light-induced cancers would not rely on selective
pressure to drive mutation propagation within cells.
Even though we have shown that CTCF binding site mutations
in melanoma are in general under neither positive nor negative
selection, single non-recurrent somatic point mutations may still
have oncogenic effects within an individual cell or cancer sample
(Kim et al., 2016). For example, one significantly differentially ex-
pressed cancer-associated gene in a TAD with a mutated CTCF
anchor motif is the tumor suppressor APC. APC had significantly
lower expression in the mutant sample than wild-type samples
(adjusted p < 0.0001, one-sample t test; Figure S3A). APC is a
component of the Wnt signaling transduction pathway, and
epigenetic silencing of APC may contribute to melanoma devel-
opment by promoting cell proliferation (Worm et al., 2004). The
observed low APC expression does not seem associated with
copy number loss or nonsense-mediated decay, as the mutant
melanoma sample identified has no copy number alterations at
the APC locus (segment mean = –0.1306, approximating a
copy number of two) and no coding mutations in the gene
body. It is possible that, in this sample, the low APC expression
may be due to dysregulation caused by disruption of loop forma-
tion by themutated anchor motif (illustrated in Figure 4C), though
this hypothesis will require further investigation. Our findings17, 2865–2872, December 13, 2016 2869
Figure 4. CTCF Motif Mutations and Study of Cancer Association in Melanoma
(A) Contingency table and p value (Fisher’s exact test) for cancer-associated and non-cancer-associated genes within loops with mutant and wild-type topo-
logically associated domain (TAD) anchor motifs. Histogram shows results from bootstrap (n = 1,000 iterations; data bins: 0.25% intervals) of proportion of
cancer-associated genes in loops with mutated anchors when mutations randomly assigned across TAD anchor motifs. Actual proportion from The Cancer
Genome Atlas (TCGA) melanomas is indicated.
(B) Variant allele frequency (VAF) of melanoma mutations within strict 13-bp CTCF motifs, CTCF ChIP-seq peaks from NHEK cells and BRAF V600E mutations.
Boxplot shows median, quartiles, maximum, and minimum. Significance is by unpaired t test. ****p < 0.0001; only significant associations are shown.
(C) Schematic of potential dysregulation ofAPC gene resulting frommutation of anchormotif for the TAD harboring theAPC transcription start site. Motif mutation
from TCGA melanoma sample TCGA-D9-A148 shown, with CTCF motif from JASPAR database (Mathelier et al., 2015). Diagram not to scale.
See also Figure S3.have important implications for how we define the function of
non-coding mutations in cancer genomes. As individual UV-
light-induced cancer genomes contain comparatively high
numbers of CTCF motif mutations, due to their ability to disrupt
CTCF binding, our study indicates the need for careful consider-
ation of these mutational events in individual cancer genome
analyses.
EXPERIMENTAL PROCEDURES
For further methodology, refer to Supplemental Experimental Procedures.
COLO829 Cell Culture
COLO-829 cells (cell line validation per Poulos et al., 2015) were cultured in
RPMI medium (Life Technologies) supplemented with 10% fetal bovine serum,
glutamax, and penicillin/streptomycin. ChIP-seq experiments were performed
as previously described (Wilson et al., 2010).2870 Cell Reports 17, 2865–2872, December 13, 2016Whole-Genome Sequencing Data Analysis
Somatic mutation data for melanoma were obtained from TCGA, with calls
made from BAM files from CGHub (Wilks et al., 2014) using Strelka (Saunders
et al., 2012) with default parameters. Somatic mutation data for SCC and BCC
were obtained from published datasets (Zheng et al., 2014). COLO829 single
nucleotide variant (SNV) mutation calls were also obtained from published da-
tasets (Craig et al., 2016).
75-bp paired-end Illumina raw sequencing reads for the COLO829 mela-
noma cell line were obtained with permission from the EGA (https://www.ebi.
ac.uk/ega/). Reads were aligned as previously described (Poulos et al., 2015).
ChIP-Sequencing Data Analysis
CTCF ChIP-seq data from NHEK cells were downloaded from ENCODE
(ENCODE Project Consortium, 2012) (GEO: GSM749707 and GSM749747).
RAD21 processed ChIP-seq ‘‘narrow peak’’ BED files were also downloaded
from ENCODE (ENCODE Project Consortium, 2012) for eight human cell types
(accession numbers in Table S2). Within each cell type, overlapping RAD21
peaks were merged.
COLO829 ChIP-seq data were aligned using Burrows-Wheeler Aligner
(BWA) (Li and Durbin, 2009), with peaks called using the Homer Suite (Heinz
et al., 2010).
Additional Datasets
XR-seq CPD repair data from UV-light-irradiated normal human skin fibro-
blast (NHF) cells (Hu et al., 2015) were obtained in Sequence Read Archive
(SRA) format (GEO: GSM1659156) and processed as previously described
(Hu et al., 2015). Time-course CPD and (6-4)PP XR-seq data for NHF cells
(Adar et al., 2016) were obtained in SRA format (GEO: GSE76391) and
processed per Supplemental Experimental Procedures. Repair reads over
pyrimidine pairs (Figures 1D and 1E) were normalized by dividing the total
strand-specific repair reads at each pyrimidine pair across all motifs, by the
XR-seq reads at that time point and by total motifs (n = 5,470) and then multi-
plying by 109.
Replication timing data for NHEK cells were obtained from ENCODE
(ENCODE Project Consortium, 2012) (GEO: GSM923445) as a bigwig file,
with data extracted using ‘‘bigWigAverageOverBed’’ tool.
Melanoma gene expression was determined from processed (level 3) RNA
sequencing (RNA-seq) data downloaded from TCGA data portal. Genes
were designated cancer associated if listed on COSMIC’s Cancer Gene
Census (retrieved April 14, 2016, containing 571 unique cancer-associated
genes). Transcription start sites (TSSs) for each gene were obtained from
the UCSC table browser.
TAD anchors, anchor motifs, and loop regions were identified from pub-
lished data of Hi-C experiments in NHEK cells (Rao et al., 2014) (GEO:
GSE63525).
CTCF Motifs and Data Analysis
Mutation profiles were generated by counting mutations at each base within
±1 kb of a motif. Counts were then normalized to mutations per megabase
per sample for each cancer type. Repair profiles counted the number of
NER CPD reads in NHF cells (non-time-course data [Hu et al., 2015]) overlap-
ping each base within ±1 kb of a motif. Repair read counts were scaled by
multiplying total read count at each base by 1,000 (Figures 2C and 2D). All pro-
files were orientated so that the motif runs from 50 to 30.
Statistical Analysis
Significance in Figures 1B, 1D, and 1E is by paired t test between samples (Fig-
ure 1B) or pyrimidine pairs (Figures 1D and 1E). Significance in Figures 2B and
2E is by Spearman’s correlation on un-binned data (graph shows binned data
points). Figure 4A shows significance by Fisher’s exact test. All other determi-
nations of significance were by unpaired t test. For analyses of significantly
differentially expressed cancer- and non-cancer-associated genes (Figures
S3A–S3C), where appropriate, a one-sample t test was performed. Also for
these analyses, a Bonferroni correction for multiple testing was applied to p
values to determine significance.
ACCESSION NUMBERS
The accession number for the COLO829 CTCF ChIP raw sequencing and pro-
cessed peak data are GEO: GSE81945.
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